NCT02408705View on ClinicalTrials.gov

Investigating the Effect of Liraglutide on the Endogenous Glucose Production During in Tye 1 Diabetes Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

May 31, 2016

Study Completion Date

May 31, 2016

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

Liraglutide

They are receiving liraglutide for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)

DRUG

Placebo

They are receiving placebo for 3 months. Dose escalation: 0.3 mg - 0.6mg - 0.9mg - 1.2mg (over 4 weeks)

DRUG

Mixed Meal Tolerance Test with paracetamol

At the beginning and end of each period (Visit 2a, 8, 9a, 15) a Mixed Meal Tolerance Test enriched paracetamol will be performed.

Trial Locations (1)

8036

Medical University Graz, Graz

Sponsors

Collaborators (1)

Novo Nordisk A/S
All Listed Sponsors
collaborator

Novo Nordisk A/S

INDUSTRY

lead

Medical University of Graz

OTHER